Jump Financial LLC Purchases Shares of 97,950 Organogenesis Holdings Inc. (NASDAQ:ORGO)

Jump Financial LLC bought a new position in shares of Organogenesis Holdings Inc. (NASDAQ:ORGO - Free Report) in the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor bought 97,950 shares of the company's stock, valued at approximately $313,000. Jump Financial LLC owned 0.08% of Organogenesis at the end of the most recent quarter.

Other large investors also recently modified their holdings of the company. Rhumbline Advisers increased its position in shares of Organogenesis by 7.1% during the fourth quarter. Rhumbline Advisers now owns 115,266 shares of the company's stock valued at $369,000 after buying an additional 7,621 shares during the period. State Street Corp raised its position in shares of Organogenesis by 0.6% in the 3rd quarter. State Street Corp now owns 1,459,767 shares of the company's stock worth $4,175,000 after acquiring an additional 9,090 shares in the last quarter. American Century Companies Inc. lifted its stake in shares of Organogenesis by 10.4% in the 4th quarter. American Century Companies Inc. now owns 98,892 shares of the company's stock valued at $316,000 after purchasing an additional 9,311 shares during the period. Wells Fargo & Company MN lifted its stake in shares of Organogenesis by 29.6% in the 4th quarter. Wells Fargo & Company MN now owns 41,471 shares of the company's stock valued at $133,000 after purchasing an additional 9,464 shares during the period. Finally, Virtu Financial LLC bought a new stake in shares of Organogenesis during the fourth quarter valued at approximately $38,000. 49.57% of the stock is owned by institutional investors.

Organogenesis Stock Up 8.2 %

Organogenesis stock traded up $0.41 during trading hours on Friday, hitting $5.37. The stock had a trading volume of 1,188,985 shares, compared to its average volume of 1,140,195. The stock's 50-day moving average price is $4.59 and its 200-day moving average price is $3.83. The stock has a market capitalization of $680.69 million, a P/E ratio of -89.37 and a beta of 1.79. Organogenesis Holdings Inc. has a 12-month low of $2.21 and a 12-month high of $6.71. The company has a quick ratio of 2.74, a current ratio of 3.09 and a debt-to-equity ratio of 0.21.

Analyst Ratings Changes

Separately, Morgan Stanley boosted their price objective on shares of Organogenesis from $4.00 to $6.00 and gave the stock an "equal weight" rating in a research note on Wednesday, March 5th.

Insider Buying and Selling

In other Organogenesis news, Director Michael Joseph Driscoll sold 25,000 shares of Organogenesis stock in a transaction that occurred on Tuesday, March 4th. The shares were sold at an average price of $5.10, for a total value of $127,500.00. Following the completion of the sale, the director now owns 166,879 shares of the company's stock, valued at approximately $851,082.90. The trade was a 13.03 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. 36.90% of the stock is owned by company insiders.

About Organogenesis

Organogenesis Holdings Inc, a regenerative medicine company, develops, manufactures, and commercializes solutions for the advanced wound care, and surgical and sports medicine markets in the United States. The company's advanced wound care products include Affinity, an amniotic membrane in which viable cells, growth factors/cytokines, and ECM proteins in the native tissue are preserved; Novachor, a chorion membrane in which viable cells, growth factors/cytokines, and ECM proteins in the native tissue are preserved; Apligraf, a bioengineered living cell therapy that produce spectrum of cytokines and growth factors; Dermagraft, a bioengineered product that produces human collagen, ECM, proteins, cytokines, and growth factors; NuShield, dehydrated placental tissue covering amnion and chorion membranes for spongy/intermediate layer intact; and PuraPly AM, an antimicrobial barrier that enables conformability and fluid drainage.